London, ON – Viron Therapeutics has been named as this year’s recipient of the prestigious Prix Galien Canada award in Biotechnology. This award is one of the highest honours in the pharmaceutical and biotechnology industry and recognizes excellence in medical and scientific research and innovation.
Viron was selected for its pioneering work developing a novel class of medicines targeting inflammatory-based disorders including acute coronary syndromes, transplant rejection, inflammatory bowel disease and rheumatoid arthritis. The company’s lead compound is now in Phase II clinical testing.
“We are extremely proud to have been awarded the Prix Galien, as it represents the highest honour in our industry,” says Neil K Warma, the company’s president and CEO. “Viron has been steadily advancing its novel drug development platform over the past several years.”
Established in 1970 in France to promote pharmaceutical research and innovation, the competition has since spread to many other countries including Canada and the United States and is now recognized internationally as the award of excellence in the industry.